Nanaomycin A

Nanaomycin A is the first selective DNMT3B inhibitor with an IC 50 of 500 nM. Nanaomycin A, a quinone antibiotics , reactivates silenced tumor suppressor genes in human cancer cells Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC 80 value of 33.1 nM . In Vitro Nanaomycin A (10-10000 nM; 72 hours) has a distinct cytotoxic effect in all three cell lines. Nanaomycin A (0.5, 5 μM; 72 hours) reveals induction of RASSF1A protein expression in A549 cells. Nanaomycin A (5 μM; 72 hours) has an 18-fold relative induction. Nanaomycin A not affects the enzymatic activity of DNMT1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: HCT116 (colon), A549 (lung), and HL60 (bone marrow) human tumor cell lines Concentration: 10, 100, 1000, 10000 nM Incubation Time: 72 hours Result: Had a distinct cytotoxic effect in all three cell lines. Western Blot AnalysisCell Line: A549 cells Concentration: 0.5, 5 μM Incubation Time: 72 hours Result: Revealed induction of RASSF1A protein expression. RT-PCRCell Line: A549 cells Concentration: 5 μM Incubation Time: 72 hours Result: Had an 18-fold relative induction. Form:Solid IC50& Target:DNMT3B 500 nM (IC 50 ) Plasmodium

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet